Amgen this week reported that the Phase III ASPIRE trial showed
better progression-free survival (PFS) and overall response rate (ORR) for
patients treated with Kyprolis (carfilzomib) in combination with lenalidomide
and dexamethasone (KRd).
Patients who had an early relapse of multiple myeloma, within one year of the initial treatment, fared better with KRd than with lenalidomide and dexamethasone (Rd) alone.
"A goal in treating relapsed multiple myeloma is to get patients into remission, and keep them in remission as long as possible. For some patients who relapse early, this may be a sign of a more aggressive disease," Amgen EVP of Research and Development Dr. Sean E. Harper said. "This analysis showed that in early relapsing multiple myeloma patients, the addition of Kyprolis to lenalidomide and dexamethasone resulted in patients living longer without their disease progressing, a significant milestone for patients living with this difficult-to-treat disease."
The secondary analysis showed that the median PFS for early relapse patients treated with KRd was 24.1 months while patients treated with Rd was 12.5 months. The results of the study were presented at the American Society of Clinical Oncology (ASCO) annual meeting.
Alerts Sign-up